Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/074873099129001055 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genome recombination on demand.
Science
January 2025
Department of Genetics, School of Medicine, Stanford University, Stanford, CA, USA.
Large genome rearrangements in mammalian cells can be generated at scale.
View Article and Find Full Text PDFThe selective sorting of miR-4432 into endothelial extracellular vesicles is controlled by a specific RNA binding protein: New Insights in the pathophysiology of venous malformations.
Br J Dermatol
January 2025
Department of Medicine (Division of Cardiology), Wilf Family Cardiovascular Research Institute, Einstein Institute for Neuroimmunology and Inflammation (INI), Einstein Institute for Aging Research, Albert Einstein College of Medicine, New York City, NY.
A review of clinical applications of pharmacokinetic simulations for a 2-month long-acting injectable formulation of aripiprazole.
Curr Med Res Opin
January 2025
Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA.
Aripiprazole 2-month ready-to-use (Ari 2MRTU) is a long-acting injectable antipsychotic that was approved for use in Europe in March 2024, for the maintenance treatment of schizophrenia in adult patients stabilized with aripiprazole; it is administered via gluteal intramuscular injection once every two months. This review examines population pharmacokinetic model-based simulations relevant to the use of Ari 2MRTU in Europe, accompanied by expert commentary that contextualizes the simulations and highlights the potential implications of the availability of Ari 2MRTU for patients, caregivers, and clinicians. Various simulations conducted across 8 weeks (representing the first dosing interval), or 32 weeks (representing maintenance dosing) demonstrated an aripiprazole exposure profile for Ari 2MRTU that was similar to aripiprazole once-monthly (AOM), but with an extended dosing interval.
View Article and Find Full Text PDFEfficient, scalable, and near-nucleotide-resolution profiling of protein occupancy in the genome with deaminases.
Proc Natl Acad Sci U S A
February 2025
Department of Cellular and Molecular Medicine, University of California, San Diego School of Medicine, La Jolla, CA 92093.
Neoadjuvant or perioperative immunotherapy for resectable melanoma: The need for biomarkers.
Eur J Cancer
January 2025
National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark. Electronic address:
Groundbreaking studies have reshaped the treatment landscape for patients with resectable stage ≥IIIB melanoma by demonstrating the benefits of neoadjuvant therapy. Data from the NADINA and SWOG S1801 trials reveal substantial improvements in event-free survival compared to adjuvant therapy alone. These studies employed distinct neoadjuvant immunotherapy approaches - ipilimumab plus nivolumab in NADINA and anti-PD-1 monotherapy in SWOG S1801 - highlighting potential differences in efficacy and toxicity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!